Ultime notizie per Evoke Pharma (NASDAQ:EVOK) Azioni

Evoke Pharma

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Evoke Pharma Inc

EVOKAI CREATIVE LABS INC by EVOKAI CREATIVE LABS INC.

EvokAI Creative Labs Inc

888 HOLDINGS PLC ORD by 888 Holdings plc.

Evoke PLC

Nantahala to nominate 2 board seats
Portion of the proceeds received from warrants executed at $8.16/share
SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused on developing treatments for gastrointestinal (GI) diseases, with a particular emphasis on GIMOTI&#xAE; (metoclopramide) nasal spray, announced today that it received approximately $3.0 million in gross proceeds from the amendment and exercise of existing warrants.
The approximately $3.0 million in gross proceeds will be used to support working capital and general corporate purposes, including advancing the commercial efforts for GIMOTI. Details of the exercised warrants can be found in the corresponding SEC filing. No new warrants were issued with these transactions which closed on September 30, 2024.

News

EVOK

Evoke Pharma Announces It Recieved $3M In Gross Proceeds From Existing Warrants And Board Expansion; Portion Of The Proceeds Received From Warrants Executed At $8.16/share

<a href="https://www.globenewswire.com/Tracker?data=kXC5zwQobnwJ5tuHPOAJ6PRRMWtoTywyxfs_zeap6YEYFsLA5wSyuoSjT52Uy9zuGU9Ty-L3lVzkhL5ffGzpYbCcDhWpxxnFV7goFgHCYRQ=">Evoke Pharma, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti&#xAE;&nbsp;(metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administration (FDA) to not approve Vanda Pharmaceuticals new drug application (NDA) for Tradipitant, an oral drug candidate for the treatment of symptoms in gastroparesis. Patients suffering from all forms of gastroparesis need additional agents to help treat this difficult disease, and we believe patients will be disappointed given the FDA's decision. Evoke continues to serve as a trusted partner for healthcare professionals and patients alike with its proven product, Gimoti&#xAE; (metoclopramide), the first and only FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults.

Biotech

General

VNDA

Evoke Pharma Reaffirms Its Commitment To Improving The Lives Of Patients Suffering From Diabetic Gastroparesis In Light Of The Recent Decision By The U.S. FDA To Not Approve Vanda Pharmaceuticals NDA For Tradipitant, An Oral Drug Candidate For The Treatment Of Symptoms In Gastroparesis

Trading Ideas

Evoke Pharma Shares Halted To The Downside; Stock Now Down -7.90%

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.06) by 1450 percent. This is a 66.07 percent decrease over losses of $(0.56) per share from the same period last year. The company reported quarterly sales of $2.55 million which missed the analyst consensus estimate of $2.98 million by 14.38 percent. This is a 125.58 percent increase over sales of $1.13 million the same period last year.

Earnings

Evoke Pharma Q2 EPS $(0.93) Misses $(0.06) Estimate, Sales $2.55M Miss $2.98M Estimate

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Evoke Pharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares ended Tuesday down 16.40% to 42 cents after the company announced a <a href="https://www.benzinga.com/pressreleases/24/07/g40036131/evoke-pharma-inc-announces-reverse-stock-split">1-for-12 reverse stock split</a> of its common stock, set to take effect at 12:01 a.m. ET on August 1, 2024. After-hours trading has it up 12.44% at 47 cents.
The reverse stock split means that every 12 shares of the company&#8217;s existing common stock will be consolidated into one share. The stock will trade on a split-adjusted basis on NASDAQ under the same symbol, EVOK, starting Aug. 1.
This reverse split, approved by shareholders at the 2024 annual meeting, will not change the par value or the authorized number of shares. Fractional shares will not be issued; instead, shareholders will receive a cash payment for any fractional shares.
Read Also: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/07/40048366/post-it-manufacturer-3m-sticks-landing-while-ford-tanks-biggest-beats-and-misses-fro">Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far</a>
<h2 class="wp-block-heading">Should I Buy, Hold or Sell My EVOK Stock?</h2>
When deciding to buy, hold or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Evoke Pharma have decreased by 75.13% in the past year. An investor who bought shares of Evoke Pharma at the beginning of the year would take a loss of $0.64 per share if they sold it today. The stock has fallen 16.7% over the past month, meaning an investor who bought shares on Jun. 1 would see a capital loss of $0.11.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Evoke Pharma stock currently has an RSI of 28.29, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
EVOK has a 52-week high of $1.67 and a 52-week low of 36 cents.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/07/40044042/job-openings-hold-steady-in-june-ahead-of-crucial-july-labor-market-data-why-this" target="_blank" rel="noreferrer noopener">Job Openings Hold Steady In June Ahead Of Crucial July Labor Market Data: Why This Analyst Expects Robust Payrolls</a></li>
</ul>

Stock Split

Why Evoke Pharma (EVOK) Stock Is Volatile

WIIM

Evoke Pharma shares are trading lower after the company announced a 1-for-12 reverse stock split.

Common Stock To Trade On Split-Adjusted Basis Under Symbol EVOK With New CUSIP 30049G302

Evoke Pharma Announces 1-For-12 Reverse Stock Split Effective August 1, 2024

Expanded State Medicaid Access for GIMOTI &nbsp;
Achieved highest ever monthly GIMOTI prescription fills in May 2024
Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer
SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=IaxjH0P_Dw9V-DZnyx7EHiHDc53dMWGu_ppA-8flLTgdd9SrJLmrooJSXiets7Rm_UcBc1djGQdXwyXCEQiG5VpJF-czatgj_k4JCdWv1K_coB5dHtgBMzQ6fBoJIDZ-">Evoke Pharma, Inc. (NASDAQ:</a><a href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE; (metoclopramide) nasal spray, announced&nbsp;updates regarding their business and commercial growth strategy. With a determined focus to ensure maximum market access for GIMOTI, Evoke continues to execute on its plan to expand net product sales throughout 2024. This update outlines the key areas of Evoke's strategic blueprint and positive updates regarding its implementation.

Evoke Pharma Reports Commercial Strategy Progress & Momentum For GIMOTI; Announced The Promotion Of Mark Kowieski To The Role Of Chief Financial Officer In May 2024

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock moved upwards by 15.6% to $1.7 during Thursday's after-market session. The company's market cap stands at $40.5 million. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares increased by 11.85% to $0.57. The company's market cap stands at $275.2 million. As per the news, the Q4 earnings report came out today. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock moved upwards by 10.0% to $0.55. The market value of their outstanding shares is at $19.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares moved upwards by 9.54% to $0.1. The company's market cap stands at $16.4 million. </li>
<li>Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) shares increased by 9.01% to $1.39. The market value of their outstanding shares is at $30.6 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) stock increased by 8.28% to $1.83. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares fell 26.5% to $3.38 during Thursday's after-market session. The market value of their outstanding shares is at $91.2 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock decreased by 10.64% to $0.42. The company's market cap stands at $3.6 million. </li>
<li>Biomerica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>) stock fell 5.0% to $0.61. The market value of their outstanding shares is at $10.2 million. </li>
<li>Applied DNA Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) shares decreased by 4.93% to $1.93. The market value of their outstanding shares is at $1.9 million. </li>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 4.89% to $0.76. The company's market cap stands at $19.8 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock declined by 4.88% to $0.39. The company's market cap stands at $2.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APDN

AXDX

BIOR

BMRA

GNLX

GOVX

HLTH

ONMD

PPBT

TIVC

12 Health Care Stocks Moving In Thursday's After-Market Session

<a href="https://www.globenewswire.com/Tracker?data=gSGhsdKbeEGcWnUKHhwFuY5TE2XsQg_9B8BJXLu56R22fjrouyoMJHGf_tbgMX2CzwFQ66uPoJ8JFLZE0IWwLOE6wMWtdeLifsk9oMzAuc92LaXNB7BkHHZNHVgnj26RjQ8k1VtqwhW_UoJ3KupDYdy46EcttqjCixUhuonrN0FoxONiLTRyV9omBvHc6Kmq4KcrNhz6d1Y5TdrRsYfZ6qx5sU-jhX-Kn_fthpckXFC7VmXDDkHRB5CXSy7iWrNWla0K3NUXsRT5BbIfqhty-fYiz3M939YMdqAxP016a-swmPA1REfVkKUsU592gDBJm4oyJSRtkFbPPyqP20dYDqlW8248j2ahuc3HkLfQTwebQwUlLmTGKwGkICB3O5NrnWqhyi5lMjku8JZ-m9VXz_0VGKcpbZ0PnO2QMHPI5Yyg8CCRSpH_TQXGWZ3svLdxIMdZ8mVtn2Otfxd5LyGfJ7Sz2H-Jtq-oFRXdqR2uzd0=">Evoke Pharma, Inc.</a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE;&nbsp;(metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C. &nbsp;

Evoke Pharma Presents Additional GIMOTI Healthcare Utilization Data Focused On Gastroparesis Care Insights In Women At DDW 2024 Conference

Guidance

Evoke Pharma Reiterates FY24 Net Revenue ~$14M Vs $14.081 Est.

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.21) by 19.05 percent. The company reported quarterly sales of $1.74 million which missed the analyst consensus estimate of $2.14 million by 18.85 percent. This is a 114.09 percent increase over sales of $810.41 thousand the same period last year.

Earnings Beats

Earnings Misses

Evoke Pharma Q1 2024 GAAP EPS $(0.17) Beats $(0.21) Estimate, Sales $1.74M Miss $2.14M Estimate

Evoke Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI&#xAE;&nbsp;(metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer. &nbsp;
"Working closely with Dave has been an absolute privilege," said Matt D'Onofrio, incoming Chief Executive Officer of Evoke Pharma. "His relentless leadership resulted in our company developing and launching a highly unique and impactful therapy for patients suffering from diabetic gastroparesis. As CEO, I am driven by the same commitment to our core mission to bring GIMOTI to more and more patients who suffer from this devastating disease. Our strategy remains unaltered and our commercial team remains committed to ensure GIMOTI reaches those in need."
"Dave's vision and dedication have been the cornerstone of Evoke Pharma's success, turning the dream of GIMOTI into a life-changing reality for patients and for that, we are incredibly grateful to him," stated Cam Garner, Chairman of Evoke Pharma Board. "Given Matt has been an influential and integral part of the team since inception, the board and I share deep confidence in Matt's leadership for the future — a vision with ambitious commercial goals and intent to enhance value for our shareholders."
In tandem with his new executive responsibilities, Mr. D'Onofrio will assume Mr. Gonyer's board seat as of March 31, 2024.

Management

Evoke Pharma Announces Senior Leadership Transition With Promotion Of Matthew J. D'Onofrio To Chief Executive Officer, As Of March 31, 2024

Evoke Pharma Sees FY24 Net Revenue ~$14M Vs $14.017M Est.

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:10 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Evoke Pharma missed estimated earnings by -18.0%, reporting an EPS of $-0.59 versus an estimate of $-0.5.
Revenue was up $880 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.11 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Evoke Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.62</td>
<td>-0.73</td>
<td>-0.58</td>
<td>-0.53</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.51</td>
<td>-0.56</td>
<td>-0.67</td>
<td>-0.54</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.26M</td>
<td>1.10M</td>
<td>1.00M</td>
<td>890K</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.56M</td>
<td>1.13M</td>
<td>810K</td>
<td>796K</td>
</tr>
</tbody>
</table>

To track all earnings releases for Evoke Pharma <a href="https://www.benzinga.com/quote/EVOK/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Evoke Pharma Q4 Earnings

Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.50) by 18 percent. The company reported quarterly sales of $1.676 million which beat the analyst consensus estimate of $1.632 million by 2.70 percent. This is a 110.55 percent increase over sales of $796.000 thousand the same period last year.

Evoke Pharma Q4 2023 GAAP EPS $(0.59) Misses $(0.50) Estimate, Sales $1.676M Beat $1.632M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Pharming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) is projected to report earnings for its fourth quarter.
&bull; ImmunoPrecise Antibodies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>) is likely to report quarterly loss at $0.07 per share on revenue of $4.50 million.
&bull; G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is projected to report quarterly earnings at $0.67 per share on revenue of $817.48 million.
&bull; Dick&#39;s Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is estimated to report quarterly earnings at $3.35 per share on revenue of $3.80 billion.
&bull; Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) is likely to report quarterly loss at $0.03 per share on revenue of $5.80 million.
&bull; Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is likely to report quarterly earnings at $0.34 per share on revenue of $405.61 million.
&bull; Weibo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WB#NASDAQ">WB</a>) is expected to report quarterly earnings at $0.49 per share on revenue of $455.09 million.
&bull; Futu Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUTU#NASDAQ">FUTU</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $331.79 million.
&bull; Akebia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>) is expected to report quarterly loss at $0.04 per share on revenue of $55.39 million.
&bull; Kandi Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KNDI#NASDAQ">KNDI</a>) is projected to report earnings for its fourth quarter.
&bull; Benson Hill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHIL#NYSE">BHIL</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $87.30 million.
&bull; KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is likely to report quarterly earnings at $0.18 per share on revenue of $2.63 billion.
&bull; Dollar Gen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) is expected to report quarterly earnings at $1.75 per share on revenue of $9.78 billion.
&bull; Hudson Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $38.02 million.
&bull; InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $30.00 million.
&bull; HF Foods Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFFG#NASDAQ">HFFG</a>) is likely to report earnings for its fourth quarter.
&bull; Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) is estimated to report earnings for its Fiscal Year 2023.
&bull; Ucloudlink Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $23.60 million.
&bull; Xunlei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNET#NASDAQ">XNET</a>) is likely to report earnings for its fourth quarter.
&bull; Build-A-Bear Workshop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) is projected to report quarterly earnings at $1.32 per share on revenue of $150.45 million.
&bull; Global X Guru Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GURU#NYSE">GURU</a>) is projected to report quarterly loss at $0.05 per share on revenue of $6.85 million.
&bull; Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) is expected to report quarterly loss at $0.36 per share on revenue of $142.31 million.
&bull; Katapult Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPLT#NASDAQ">KPLT</a>) is expected to report quarterly loss at $1.79 per share on revenue of $55.81 million.
&bull; UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.68 per share on revenue of $22.57 million.
&bull; Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) is projected to report quarterly loss at $0.05 per share on revenue of $47.05 million.
&bull; RumbleON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBL#NASDAQ">RMBL</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $339.48 million.
&bull; Alarum Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAR#NASDAQ">ALAR</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $7.00 million.
&bull; Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is estimated to report quarterly loss at $0.25 per share on revenue of $360 thousand.
&bull; United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is projected to report earnings for its first quarter.
&bull; BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is likely to report earnings for its fourth quarter.
&bull; Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $166.15 million.
&bull; Mondee Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOND#NASDAQ">MOND</a>) is likely to report quarterly loss at $0.12 per share on revenue of $55.00 million.
&bull; GoHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOCO#NASDAQ">GOCO</a>) is likely to report quarterly earnings at $2.72 per share on revenue of $363.88 million.
&bull; SecureWorks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWX#NASDAQ">SCWX</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $87.18 million.
&bull; Aveanna Healthcare Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>) is projected to report quarterly loss at $0.02 per share on revenue of $467.40 million.
&bull; PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) is expected to report quarterly loss at $0.47 per share on revenue of $2.47 million.
&bull; Canadian Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSIQ#NASDAQ">CSIQ</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $1.69 billion.
&bull; CION Invt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CION#NYSE">CION</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $58.33 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) is expected to report quarterly loss at $0.09 per share on revenue of $36.93 million.
&bull; Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $56.87 million.
&bull; Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $216.46 million.
&bull; Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) is likely to report quarterly earnings at $7.53 per share on revenue of $3.53 billion.
&bull; Skillz (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKLZ#NYSE">SKLZ</a>) is projected to report quarterly loss at $1.41 per share on revenue of $38.09 million.
&bull; Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is expected to report quarterly loss at $0.13 per share on revenue of $3.22 million.
&bull; Smartsheet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMAR#NYSE">SMAR</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $255.38 million.
&bull; Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is expected to report quarterly loss at $0.26 per share on revenue of $93.53 million.
&bull; Despegar.com (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DESP#NYSE">DESP</a>) is projected to report quarterly earnings at $0.17 per share on revenue of $191.43 million.
&bull; Frequency Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEIM#NASDAQ">FEIM</a>) is projected to report earnings for its third quarter.
&bull; Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) is projected to report earnings for its fourth quarter.
&bull; American Vanguard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) is likely to report quarterly earnings at $0.27 per share on revenue of $172.90 million.
&bull; The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $98.04 million.
&bull; Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is likely to report earnings for its fourth quarter.
&bull; Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) is likely to report quarterly loss at $0.14 per share on revenue of $1.25 million.
&bull; Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) is likely to report quarterly loss at $0.50 per share on revenue of $1.63 million.
&bull; Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $12.75 million.
&bull; Kopin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOPN#NASDAQ">KOPN</a>) is projected to report quarterly loss at $0.02 per share on revenue of $9.03 million.
&bull; Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) is projected to report earnings for its fourth quarter.
&bull; Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) is projected to report quarterly earnings at $0.26 per share on revenue of $275.87 million.
&bull; Tilly&#39;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is projected to report quarterly loss at $0.22 per share on revenue of $171.65 million.
&bull; CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) is projected to report quarterly loss at $0.14 per share on revenue of $9.28 million.
&bull; Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is projected to report quarterly earnings at $0.22 per share on revenue of $125.84 million.
&bull; Allogene Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLO#NASDAQ">ALLO</a>) is projected to report quarterly loss at $0.45 per share on revenue of $20 thousand.
&bull; Adecoagro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) is expected to report earnings for its fourth quarter.
&bull; Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is expected to report quarterly loss at $0.12 per share on revenue of $59.72 million.
&bull; Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is estimated to report quarterly loss at $0.32 per share on revenue of $80.97 million.
&bull; Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $124.61 million.
&bull; Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $95.48 million.
&bull; Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is estimated to report earnings for its fourth quarter.
&bull; Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) is likely to report quarterly loss at $0.03 per share on revenue of $256.27 million.
&bull; Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is projected to report quarterly earnings at $0.12 per share on revenue of $89.55 million.
&bull; Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is expected to report quarterly loss at $0.04 per share on revenue of $7.70 million.
&bull; EverCommerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVCM#NASDAQ">EVCM</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $172.41 million.
&bull; Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is expected to report quarterly loss at $0.20 per share on revenue of $3.62 million.
&bull; Acacia Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACTG#NASDAQ">ACTG</a>) is likely to report quarterly earnings at $0.07 per share on revenue of $8.00 million.
&bull; Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) is estimated to report quarterly loss at $0.05 per share on revenue of $483.69 million.
&bull; Wheaton Precious Metals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPM#NYSE">WPM</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $291.55 million.
&bull; Spruce Power Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPRU#NYSE">SPRU</a>) is likely to report earnings for its fourth quarter.
&bull; aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFE#NASDAQ">LIFE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $50 thousand.
&bull; Clipper Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLPR#NYSE">CLPR</a>) is projected to report earnings for its fourth quarter.
&bull; Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is likely to report quarterly earnings at $4.38 per share on revenue of $5.14 billion.
&bull; Heritage Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HGBL#NASDAQ">HGBL</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $15.35 million.
&bull; NuScale Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) is projected to report quarterly loss at $0.14 per share on revenue of $8.94 million.
&bull; Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) is expected to report quarterly loss at $0.01 per share on revenue of $43.93 million.
&bull; Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is likely to report earnings for its Fiscal Year 2023.
&bull; FutureFuel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FF#NYSE">FF</a>) is likely to report earnings for its fourth quarter.
&bull; Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $47.00 million.
&bull; Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) is likely to report quarterly loss at $0.31 per share on revenue of $35.64 million.
&bull; PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) is projected to report quarterly earnings at $0.15 per share on revenue of $110.40 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ACTG

ADBE

AGEN

AGRO

AKBA

ALAR

ALLO

ALTG

AMPS

AUTL

AVAH

Mobile Infrastructure Corporation Common Stock

BEEP

BEKE

BHIL

BKTI

BLND

BLNK

BRLT

CDLX

CION

CLPR

CNTY

CODX

CSIQ

CTSO

DESP

ETON

EVCM

FEIM

FTHM

FUTU

GETY

GIII

GOCO

GURU

HFFG

HGBL

HSON

INFU

KNDI

KODK

KOPN

KPLT

LIFE

MCHX

MNTK

MOLN

MOMO

MOND

PHAR

PSQH

RGTI

RMBL

SCWX

SKLZ

SMAR

Spruce Power Holding Corporation Class A Common Stock

SPRU

STKS

TLYS

ULTA

URGN

VXRT

XNET

ZUMZ

Earnings Scheduled For March 14, 2024

<h3>Gainers</h3>
<ul>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares rose 18.54% to $0.76. The market value of their outstanding shares is at $6.4 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock rose 11.75% to $4.84. The company's market cap stands at $25.0 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares moved upwards by 10.49% to $0.83. The company's market cap stands at $22.5 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) stock moved upwards by 9.99% to $1.21. The market value of their outstanding shares is at $17.8 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares increased by 9.87% to $1.78. The company's market cap stands at $50.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock declined by 75.2% to $1.29 during Wednesday's after-market session. The market value of their outstanding shares is at $52.5 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) stock fell 9.1% to $0.59. The market value of their outstanding shares is at $21.0 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock fell 8.58% to $0.38. The market value of their outstanding shares is at $20.2 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock decreased by 7.9% to $5.6. The market value of their outstanding shares is at $72.8 million. </li>
<li>Bright Green (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares declined by 7.48% to $0.26. The company's market cap stands at $47.8 million. </li>
<li>Lipocine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPCN#NASDAQ">LPCN</a>) stock declined by 7.1% to $4.45. The company's market cap stands at $23.6 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGXX

CYTH

GLTO

LPCN

MIRA

NCNA

SPRB

12 Health Care Stocks Moving In Wednesday's After-Market Session

<a href="https://www.sec.gov/Archives/edgar/data/1105806/000093583624000282/evok13g.htm" title="https://www.sec.gov/Archives/edgar/data/1105806/000093583624000282/evok13g.htm">https://www.sec.gov/Archives/edgar/data/1105806/000093583624000282/evok13g.htm</a>

Laurence W. Lytton Reports In 13G Filing A 9.99% Stake In Evoke Pharma

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evoke Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/evok-stock-quote/">EVOK</a>) just reported results for the first quarter of 2024.<ul><li>Evoke Pharma reported earnings per share of -17 cents. This was above the analyst estimate for EPS of -21 cents.</li><li>The company reported revenue of $1.74 million.</li><li>This was 18.93% worse than the analyst estimate for revenue of $2.14 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/evok-stock-earnings-evoke-pharma-for-q1-of-2024/">EVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVOK Stock Earnings: Evoke Pharma Beats EPS, Misses Revenue for Q1 2024

Evoke Pharma GAAP EPS of -$0.17 beats by $0.04, revenue of $1.73M misses by $0.41M

Evoke Pharma (EVOK) has provided an announcement. Evoke Pharma, Inc. has seen pivotal developments, including the appointment of Mark A. Kowieski a...

Evoke Pharma Announces Executive Changes and Expansion Plans

Evoke Pharma appoints Mark Kowieski as CFO

Evoke Pharma announces 1-for-12 reverse stock split

Evoke Pharma GAAP EPS of -$0.93, revenue of $2.55M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Evoke Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/evok-stock-quote/">EVOK</a>) just reported results for the second quarter of 2024.<ul><li>Evoke Pharma reported earnings per share of -93 cents. This was below the analyst estimate for EPS of -6 cents.</li><li>The company reported revenue of $2.55 million.</li><li>This was 14.40% worse than the analyst estimate for revenue of $2.98 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/evok-stock-earnings-evoke-pharma-for-q2-of-2024/">EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024

Evoke Pharma files for mixed shelf offering

Evoke Pharma files for $50M mixed securities shelf

Evoke Pharma announces proceeds from existing warrants and board expansion

Press Releases

Evoke Pharma Reports First Quarter 2024 Financial Results

Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

Health Care

Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI

Evoke Pharma, Inc. Announces Reverse Stock Split

Evoke Pharma, Inc. Supports Gastroparesis Awareness Month

Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results

Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference

Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments

Comments

Evoke Pharma

Notizie

Ultime notizie per Evoke Pharma (NASDAQ:EVOK) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO